Main menu

In a commentary published in Science Translational Medicine this week, cardiologist Eric Topol bemoans physician reluctance for adopting pharmacogenetic testing, but applauds pharmacy benefit managers Medco and CVS Caremark for stepping in to conduct clinical utility studies and introduce genetic testing in a portion of their client base to gauge the impact on patient outcomes and healthcare savings.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.